FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2346665543> ?p ?o ?g. }

• W2346665543 abstract "Abstract Background Follicular (FL), marginal zone (MZL), mantle cell (MCL) lymphomas, and lymphoplasmacytic lymphomas are indolent non-Hodgkin's lymphomas (NHL) that tend to recur multiple times with decreasing intervals of remissions. Vorinostat is an orally administered histone deacetylase inhibitor. Previously, we observed a single agent overall response rate (ORR) of 29% for vorinostat and a complete remission rate (CR) rate of 14% in indolent lymphomas (Kirschbaum 2009). Preclinical data suggests enhanced activity for the combination of vorinostat plus rituximab. We report the final results of a phase II study of the combination of vorinostat plus rituximab with correlative assays. Methods This is a two-stage phase II study in patients with newly diagnosed, relapsed or refractory indolent NHL. Vorinostat was given at 200 mg PO twice daily for 14 consecutive days on a 21 day cycle. Rituximab was given on day 1 of each cycle. CT scanning and/or FDG-PET were performed after every three cycles. The primary endpoint was the overall response rate according to Revised Cheson Criteria. Immune cytokine analysis was performed on serum samples drawn on day 0 and day 14 of treatment using Luminex X-MAP bead array. Results 30 patients were accrued with 28 eligible (2 ineligible tumor types). See Table 1 for baseline characteristics. The overall response (CR+PR) rate was 46% (13/28), and CR rate was 39% (11/28). The ORR and CR for previously untreated patients was 67% (4/6, all CR). The ORR for relapsed/refractory patients was 41% (9/22), with a CR rate of 32% (7/22). By histology, the ORR was 50% (11/22) and CR was 45% (10/22) for FL, 33.3% (1/3) for MCL (PR), 50% (1/2) for MZL (CR), and 0/1 for lymphoplasmacytic lymphoma. The median PFS was 38.2 months (95% CI: 14.4, 51.0) for all patients, 21.1 months (95% CI: 8.5, 51.0) for previously treated patients, and not-reached for untreated patients. Figure 1 shows the PFS of patients in CR and PR versus others. Patients who achieved CR were allowed to discontinue treatment and return to treatment upon progression. 10/13 CRs were progression-free with a median follow-up of 14.4 months (range 4-48 months). 2/3 patients who relapsed achieved CR again after resuming therapy. Of non-responders, 8 patients achieved stable disease for at least 9 cycles with one SD for 69 cycles. The disease control rate for >9 cycles (CR+PR+SD>9 cycles) was 75% (21/28). Five patients were taken off study for reasons other than progression (2 patient's choice, 1 to transplant, 1 for violation, and 1 physician choice). The median time to treatment failure for all patients was 17.8 months, 95% CI: (6.2, 51). Treatment was well tolerated. Grade 4 toxicities possibly attributable to study drug included neutropenia (n=1), incidental asymptomatic thrombosis (n=4), and thrombocytopenia (n=2). Grade 3 possibly related toxicities >20% included fatigue (n=9, 32%) and lymphopenia (n=7, 25%). The thromboses were asymptomatic pulmonary embolism discovered incidentally on CT scan, and resulted in amending the study to include 40 mg enoxaparin as prophylaxis, resulting in no further thromboses identified. Vorinostat plus rituximab reduced the levels of pro-inflammatory cytokines such as IL-2, INF-g, TNF-a, and IL-6. 8 of the 16 cytokine markers showed statistical decrease (p<0.05) on day 14 as compared to day 0 (IL1RA, IL2R, IL12p40p70, MIG, EOTAXIN, MCP1, EGF, and FGFBasic), and none showed a significant increase. However, the cytokine measurements on the two days and the observed changes did not distinguish between responders and non-responders. Conclusions The combination of vorinostat with rituximab is well tolerated, and showed encouraging activity against newly diagnosed and relapsed/refractory indolent NHL. Durable responses can be achieved and retreatment can lead to 2nd CR. The activity observed warrants multicenter evaluation of vorinostat with rituximab in patients with indolent lymphoma. Disclosures: Off Label Use: use of vorinostat and rituximab to treat indolent NHL." @default.
• W2346665543 created "2016-06-24" @default.
• W2346665543 creator A5004358801 @default.
• W2346665543 creator A5005565037 @default.
• W2346665543 creator A5014400968 @default.
• W2346665543 creator A5016425718 @default.
• W2346665543 creator A5022766377 @default.
• W2346665543 creator A5039374832 @default.
• W2346665543 creator A5052032114 @default.
• W2346665543 creator A5074672999 @default.
• W2346665543 creator A5075903729 @default.
• W2346665543 creator A5081676218 @default.
• W2346665543 creator A5082853715 @default.
• W2346665543 date "2013-11-15" @default.
• W2346665543 modified "2023-09-28" @default.
• W2346665543 title "Final Results Of A Phase 2 Study Of Vorinostat Plus Rituximab In Newly Diagnosed, Relapsed Or Refractory Indolent Non-Hodgkin's Lymphoma" @default.
• W2346665543 doi "https://doi.org/10.1182/blood.v122.21.4398.4398" @default.
• W2346665543 hasPublicationYear "2013" @default.
• W2346665543 type Work @default.
• W2346665543 sameAs 2346665543 @default.
• W2346665543 citedByCount "1" @default.
• W2346665543 countsByYear W23466655432016 @default.
• W2346665543 crossrefType "journal-article" @default.
• W2346665543 hasAuthorship W2346665543A5004358801 @default.
• W2346665543 hasAuthorship W2346665543A5005565037 @default.
• W2346665543 hasAuthorship W2346665543A5014400968 @default.
• W2346665543 hasAuthorship W2346665543A5016425718 @default.
• W2346665543 hasAuthorship W2346665543A5022766377 @default.
• W2346665543 hasAuthorship W2346665543A5039374832 @default.
• W2346665543 hasAuthorship W2346665543A5052032114 @default.
• W2346665543 hasAuthorship W2346665543A5074672999 @default.
• W2346665543 hasAuthorship W2346665543A5075903729 @default.
• W2346665543 hasAuthorship W2346665543A5081676218 @default.
• W2346665543 hasAuthorship W2346665543A5082853715 @default.
• W2346665543 hasConcept C104317684 @default.
• W2346665543 hasConcept C121332964 @default.
• W2346665543 hasConcept C126322002 @default.
• W2346665543 hasConcept C142424586 @default.
• W2346665543 hasConcept C143998085 @default.
• W2346665543 hasConcept C185592680 @default.
• W2346665543 hasConcept C197934379 @default.
• W2346665543 hasConcept C2776262904 @default.
• W2346665543 hasConcept C2776694085 @default.
• W2346665543 hasConcept C2777058707 @default.
• W2346665543 hasConcept C2777525834 @default.
• W2346665543 hasConcept C2778305200 @default.
• W2346665543 hasConcept C2778375690 @default.
• W2346665543 hasConcept C2778822529 @default.
• W2346665543 hasConcept C2779338263 @default.
• W2346665543 hasConcept C2780653079 @default.
• W2346665543 hasConcept C31760486 @default.
• W2346665543 hasConcept C55493867 @default.
• W2346665543 hasConcept C64927066 @default.
• W2346665543 hasConcept C71924100 @default.
• W2346665543 hasConcept C87355193 @default.
• W2346665543 hasConcept C90924648 @default.
• W2346665543 hasConceptScore W2346665543C104317684 @default.
• W2346665543 hasConceptScore W2346665543C121332964 @default.
• W2346665543 hasConceptScore W2346665543C126322002 @default.
• W2346665543 hasConceptScore W2346665543C142424586 @default.
• W2346665543 hasConceptScore W2346665543C143998085 @default.
• W2346665543 hasConceptScore W2346665543C185592680 @default.
• W2346665543 hasConceptScore W2346665543C197934379 @default.
• W2346665543 hasConceptScore W2346665543C2776262904 @default.
• W2346665543 hasConceptScore W2346665543C2776694085 @default.
• W2346665543 hasConceptScore W2346665543C2777058707 @default.
• W2346665543 hasConceptScore W2346665543C2777525834 @default.
• W2346665543 hasConceptScore W2346665543C2778305200 @default.
• W2346665543 hasConceptScore W2346665543C2778375690 @default.
• W2346665543 hasConceptScore W2346665543C2778822529 @default.
• W2346665543 hasConceptScore W2346665543C2779338263 @default.
• W2346665543 hasConceptScore W2346665543C2780653079 @default.
• W2346665543 hasConceptScore W2346665543C31760486 @default.
• W2346665543 hasConceptScore W2346665543C55493867 @default.
• W2346665543 hasConceptScore W2346665543C64927066 @default.
• W2346665543 hasConceptScore W2346665543C71924100 @default.
• W2346665543 hasConceptScore W2346665543C87355193 @default.
• W2346665543 hasConceptScore W2346665543C90924648 @default.
• W2346665543 hasLocation W23466655431 @default.
• W2346665543 hasOpenAccess W2346665543 @default.
• W2346665543 hasPrimaryLocation W23466655431 @default.
• W2346665543 hasRelatedWork W2326926256 @default.
• W2346665543 hasRelatedWork W2405898030 @default.
• W2346665543 hasRelatedWork W2467528896 @default.
• W2346665543 hasRelatedWork W2543829333 @default.
• W2346665543 hasRelatedWork W2550264021 @default.
• W2346665543 hasRelatedWork W2560299325 @default.
• W2346665543 hasRelatedWork W2560601057 @default.
• W2346665543 hasRelatedWork W2573169865 @default.
• W2346665543 hasRelatedWork W2583445401 @default.
• W2346665543 hasRelatedWork W2586530523 @default.
• W2346665543 hasRelatedWork W2587938265 @default.
• W2346665543 hasRelatedWork W2588069722 @default.
• W2346665543 hasRelatedWork W2590111115 @default.
• W2346665543 hasRelatedWork W2590629059 @default.
• W2346665543 hasRelatedWork W2594820239 @default.
• W2346665543 hasRelatedWork W2908833725 @default.
• W2346665543 hasRelatedWork W3030292181 @default.
• W2346665543 hasRelatedWork W3209145154 @default.
• W2346665543 hasRelatedWork W3210051517 @default.

• next